Peanut Allergy clinical trials at UCSF
2 in progress, 1 open to eligible people
Showing trials for
Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
open to eligible people ages 4-7
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
San Francisco, California and other locations
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Sorry, accepting new patients by invitation only
Open-label, follow-up study for subjects who completed the EPITOPE study.
San Francisco, California and other locations
Our lead scientists for Peanut Allergy research studies include Morna Dorsey.
Last updated: